中國網(wǎng)站品牌欄目（頻道）
美國食品藥品監(jiān)督管理局日前對(duì)法國歐萊雅集團(tuán)發(fā)出警告，要求其下屬的蘭蔻美國分公司停止在蘭蔻系列護(hù)膚品廣告中使用類似藥品功效的描述語言。藥監(jiān)局表示，蘭蔻系列的精華肌底修護(hù)晚霜和菁純臻顏再生眼霜等產(chǎn)品廣告稱這些產(chǎn)品可以“提升基因活力”或“刺激細(xì)胞再生”以達(dá)到延緩衰老的功效。警告信指出，任何旨在對(duì)人體結(jié)構(gòu)和功能產(chǎn)生影響的產(chǎn)品均應(yīng)被歸為藥物，而未向藥監(jiān)局提出申請(qǐng)并證明其產(chǎn)品的安全和功效的公司是不能在美國銷售這些藥物的。藥監(jiān)局稱，如果不修正上述廣告詞，他們將采取強(qiáng)制措施，比如沒收產(chǎn)品或?qū)ιa(chǎn)商和銷售商實(shí)行禁令等。
 |
|
Lancome USA, a L'Oreal unit, claimed some of its skin creams could "boost the activity of genes" or "stimulate cell regeneration" to reduce signs of aging. |
Regulators warned L'Oreal, the world's biggest cosmetics group, to stop advertising skincare products using language that makes them sound like drugs.
The U.S. Food and Drug Administration said Lancome USA, a L'Oreal unit, claimed some of its skin creams could "boost the activity of genes" or "stimulate cell regeneration" to reduce signs of aging.
Any product that is intended to affect the structure or function of the human body is classified as a drug, the FDA said, according to a warning letter posted on its website on Tuesday.
Companies are not allowed to sell drugs in the United States without submitting an application to the FDA proving their products are safe and effective and then winning FDA approval.
L'Oreal, a French company, was not immediately available for comment.
Some of the products mentioned in the letter, dated September 7, include Genifique Repair Youth Activating Night Cream and Absolue Eye Precious Cells Advanced Regenerating and Reconstructing Eye Cream.
On its website, Lancome describes the Genifique Repair cream, which costs $98 for a 1.7-ounce container, as "our first night care that boosts the activity of genes." The company cites an in-vitro test on genes to back up the claim.
The FDA said failure to fix the advertising claims could lead to enforcement actions, such as seizure of the products and injunctions against their manufacturers and distributors.
相關(guān)閱讀
(Agencies)
（中國日?qǐng)?bào)網(wǎng)英語點(diǎn)津 Helen ）
 |
 |
 |
 |
 |
 |
